This was an 8-week, double-blind, placebo-controlled, parallel-group trial conducted across two sites: D. Y. Patil Medical College (Navi Mumbai, India) and Clinical Research Australia (Perth, Australia). The intervention used KSM-66 Ashwagandha — a standardized, aqueous-extracted, root-only extract standardized to >5% withanolides by HPLC.
Participants were healthy children with parent-reported concerns about attention, concentration, or memory. Children with formal diagnoses of ADHD, psychiatric disorders, or learning disabilities were excluded, as were those taking pharmaceutical medications affecting cognition.
Primary outcomes were measured using the Computerized Mental Performance Assessment System (COMPASS), a validated battery assessing working memory, processing speed, attention, and episodic memory. Secondary outcomes included the SDSC (sleep), PROMIS-Fatigue, SDQ, and BRIEF-2 — all parent-reported.
Multivariate analysis showed a statistically significant overall improvement in Speed of Information Processing in the ARE group versus placebo (p = 0.040). Individual task analyses revealed the following significant between-group differences:
| Cognitive Domain | Task | p-value | Effect Size (d) |
|---|---|---|---|
| Processing Speed | Choice reaction time (ms) | 0.040 | d = 0.54 (moderate) |
| Episodic Memory | Delayed word recall (%) | 0.038 | d = 0.59 (moderate) |
| Executive Function | Stroop task accuracy (%) | 0.021 | d = 0.61 (moderate-large) |
| Working Memory | Corsi block span score | 0.013 | d = 0.66 (moderate-large) |
| Accuracy of Attention | Choice reaction time accuracy (%) | 0.005 | d = 0.75 (large) |
Strong trends (not reaching significance after between-group comparison) were also observed in picture recognition, word recognition, and digit vigilance response times, with effect sizes in the 0.40–0.44 range — worth noting for future, larger trials.
Corsi block span is a visuospatial working memory task analogous to digit span — improvements here suggest enhanced short-term visuospatial retention. Stroop task accuracy reflects inhibitory control and executive attention — the ability to suppress a prepotent response. Delayed word recall measures the retention of information over time, a proxy for consolidation processes relevant to learning and academic performance.
Notably, there were no significant between-group differences on the SDQ, BRIEF-2, or PROMIS-fatigue scores — though within-group improvements in ARE recipients were observed on all BRIEF-2 domains (p < 0.0001). This dissociation between objective computerized task performance and parent-reported behavioral ratings is clinically relevant and may suggest that objective cognitive gains precede behavioral changes observable by parents.
The Sleep Disturbance Scale for Children (SDSC) showed a statistically significant between-group difference at week 8 (p = 0.035, d = 0.51). While both groups showed some reduction in total sleep disturbance scores, the ARE group demonstrated a greater and more clinically meaningful improvement.
The SDSC captures six sleep domains: difficulty initiating and maintaining sleep (DIMS), sleep breathing disorders, excessive somnolence, sleep-wake transition disorders, disorders of arousal, and sleep hyperhidrosis. The study did not report domain-level breakdown for between-group comparisons, limiting our ability to identify which aspect of sleep was most affected.
The proposed mechanism involves ARE’s GABA-mimetic activity and HPA axis modulation — both plausible pathways in a pediatric population where stress-related sleep disruption is common. Improved sleep quality also has downstream implications for cognitive performance, making it difficult to fully disentangle which effect drove the other.
The frequency and nature of adverse events were comparable between groups. All events were mild and transient. This is consistent with the established safety profile of KSM-66 in adult populations and provides preliminary reassurance for short-term pediatric use at this dose.
Ashwagandha’s cognitive effects are attributed to a suite of bioactive compounds — primarily withanolides (steroidal lactones), sitoindosides, and alkaloids. Several mechanistic pathways have been proposed, though human mechanistic data in children are absent:
ARE has been shown to reduce cortisol levels in adults, suggesting downstream effects on stress-related cognitive load. Chronic subclinical stress in children can impair prefrontal cortical function, working memory, and sleep architecture — all areas where ARE showed improvement in this trial.
Withanolides have demonstrated GABA-A receptor activity, which may account for both anxiolytic and sleep-promoting effects. This is the most pharmacologically plausible mechanism for the observed sleep improvements.
Preclinical data suggest ARE promotes neurite outgrowth, upregulates BDNF, and reduces oxidative stress in hippocampal neurons — mechanisms relevant to episodic memory consolidation and synaptic plasticity during a critical developmental window.
ARE has been associated with acetylcholinesterase inhibitory activity, which may contribute to improvements in verbal memory and attention — consistent with the delayed word recall and Stroop findings in this study.
This trial fills a meaningful gap. Despite widespread clinical and parental interest in botanical cognitive support for children, robust pediatric trial data have been essentially nonexistent for Ashwagandha. The study population is also clinically relevant: healthy children with subclinical attentional concerns attending mainstream schooling.
For providers, the most actionable findings are in the objective COMPASS task data. Processing speed, working memory, and inhibitory control improvements were detected on a standardized, computerized battery, not just on parent perception scales. This reduces, though does not eliminate, concerns about placebo inflation.
The dose used (150 mg KSM-66 BID = 300 mg/day) is conservative relative to adult studies (600–1000 mg/day are common) and was well-tolerated. The gummy delivery format, while pragmatic for pediatric compliance, introduces minor concerns around standardization and dose accuracy compared to capsule or powder forms, though the manufacturer controlled formulation.
Taken together, this study provides sufficient signal to warrant continued investigation and supports thoughtful clinical consideration of ARE in healthy children with mild, subclinical cognitive or sleep concerns, particularly where families are seeking non-pharmaceutical options and the risk-benefit profile favors conservative botanical intervention.
